EPA:ALVIO - Euronext Paris - Matif - FR0010095596 - Common Stock - Currency: EUR
EPA:ALVIO (3/7/2025, 7:00:00 PM)
0.0545
+0 (+2.83%)
The current stock price of ALVIO.PA is 0.0545 EUR. In the past month the price increased by 1.3%. In the past year, price decreased by -50.68%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
4AB.DE | ABBVIE INC | 21.07 | 346.68B | ||
1ABBV.MI | ABBVIE INC | 20.82 | 342.48B | ||
AMG.DE | AMGEN INC | 16.43 | 161.21B | ||
1AMGN.MI | AMGEN INC | 15.84 | 160.89B | ||
1GILD.MI | GILEAD SCIENCES INC | 25.67 | 135.84B | ||
GIS.DE | GILEAD SCIENCES INC | 25.39 | 134.40B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | 1667.04 | 115.58B | ||
ARGX.BR | ARGENX SE | 253.61 | 33.75B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 24.36B | ||
IDP.DE | BIOGEN INC | 9.25 | 20.54B | ||
1BIIB.MI | BIOGEN INC | 8.39 | 19.21B | ||
0QF.DE | MODERNA INC | N/A | 13.19B |
Valerio Therapeutics SA is a is a clinical-stage biotechnology company, which engages in the development of drugs for the treatment of orphan diseases. The company is headquartered in Paris, Ile-De-France and currently employs 38 full-time employees. The company went IPO on 2005-07-12. The firm targets tumor DNA functions through unparalleled mechanisms of action in the sought-after field of DNA damage response (DDR). The company aims at holding a portfolio of advanced programs targeting severe pathologies with unmet clinical needs. The company has two programs in clinical development stage: Livatag, a doxorubicin Transdrag in Phase III, for the treatment of primary liver cancer, and Validive, a clonidine Lauriad in Phase II, for treatment of radio/chemo-induced severe oral mucositis at patients with head and neck cancer. The company also has one registered product in the United States, Beleodaq/ belinostat, for the treatment of peripheral T-Cell lymphoma (PTCL) and opportunities for further development; and two initial drugs registered in Europe and the United States: Loramyc/ Oravig for the treatment of oropharyngeal candidiasis, and Sitavig for the treatment of recurring herpes labialis.
VALERIO TX
49 boulevard du General Martial Valin
Paris ILE-DE-FRANCE FR
Employees: 38
Company Website: https://www.onxeo.com/
Investor Relations: http://www.onxeo.com/investors-en/
Phone: 33145587600
The current stock price of ALVIO.PA is 0.0545 EUR. The price increased by 2.83% in the last trading session.
The exchange symbol of VALERIO TX is ALVIO and it is listed on the Euronext Paris - Matif exchange.
ALVIO.PA stock is listed on the Euronext Paris - Matif exchange.
7 analysts have analysed ALVIO.PA and the average price target is 0.01 EUR. This implies a price decrease of -81.28% is expected in the next year compared to the current price of 0.0545. Check the VALERIO TX stock analysts ratings, price target forecast and up-and down grades for more detailed information.
VALERIO TX (ALVIO.PA) has a market capitalization of 8.41M EUR. This makes ALVIO.PA a Nano Cap stock.
VALERIO TX (ALVIO.PA) currently has 38 employees.
VALERIO TX (ALVIO.PA) has a resistance level at 0.07. Check the full technical report for a detailed analysis of ALVIO.PA support and resistance levels.
The Revenue of VALERIO TX (ALVIO.PA) is expected to decline by -100% in the next year. Check the estimates tab for more information on the ALVIO.PA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ALVIO.PA does not pay a dividend.
VALERIO TX (ALVIO.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.12).
ChartMill assigns a technical rating of 1 / 10 to ALVIO.PA. When comparing the yearly performance of all stocks, ALVIO.PA is a bad performer in the overall market: 97.57% of all stocks are doing better.
ChartMill assigns a fundamental rating of 1 / 10 to ALVIO.PA. ALVIO.PA may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months ALVIO.PA reported a non-GAAP Earnings per Share(EPS) of -0.12. The EPS increased by 31.63% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -67% | ||
ROE | -488.76% | ||
Debt/Equity | 2.88 |
ChartMill assigns a Buy % Consensus number of 34% to ALVIO.PA. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of -136.11% and a revenue growth -100% for ALVIO.PA